Institutions buy into ‘potstock’ buzz
MGC Pharmaceuticals (ASX:MXC) has offered more evidence that the ‘potstock’ buzz is real – closing a $5 million capital raise “multiple times oversubscribed”.
The medical cannabis player told the market this morning that institutional and sophisticated investors had applied for $3.5 million worth of shares raised at 4.4c each – with a free attaching option exercisable at 6.5c available for every three shares subscribed for.
MXC, however, soon found that demand outweighed supply and so made another $1.5 million worth of shares available – bringing the bookbuild closing at $5 million.
The shares were offered at a 19% discount on its previous trading price.
Additional shareholders will be given a chance to buy into the action, however, with MXC also announcing a priority rights offer at the same price – with punters given the opportunity to buy up to $15,000 worth of shares.
The PRO will also come with a free attaching option and MXC is aiming to raise another $2 million from this, although it has set aside another $500,000 worth of shares in case of another oversubscription.
The company said the funds raised from the offers would go towards a number of things, including: the construction of a Slovenian medical cannabis growing facility; a research lab and cannabidiol extraction centre; and to continue the development of its push into Australia.
Early in April it announced a five-pronged plan to enter the Australian market – with the aim of taking advantage of what the University of Sydney has labelled a $150 million opportunity.
The medicinal cannabis player had focused on the European market through the development of cosmetic products derived from cannabidiol – but has recently pivoted to become more of a pharmaceutical player.
It now, however, has its sights set on the Australian market which has opened up following a series of positive legislative changes allowing for cannabis to be grown for medical purposes.
These changes include things such as downgrading cannabis from the prohibited list to a lower class of medical drug which contains things such as morphine.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.